Skip to content
Business Times – Lifestyle
Author:
Santhera Pharmaceuticals Holding AG
Santhera Signs Distribution Agreement with SteinCares for AGAMREE® (Vamorolone) in 31 countries across Latin America and the Caribbean
November 12, 2026
Santhera’s Licensing Partner, Nxera Pharma, Submits Marketing Authorization Application for AGAMREE® (Vamorolone) in South Korea
October 23, 2026
Santhera Pharmaceuticals Half Year Results for the six months ending 30 June 2026
September 30, 2026
Santhera Expands Biomedica Agreement to Extend AGAMREE® (Vamorolone) Distribution Across Central Asia and the Caucasus
July 13, 2026
Santhera Notes Topline Results from Catalyst Pharmaceuticals’ Phase 1 Clinical Study of AGAMREE®
July 1, 2026
Santhera Announces Orphan Drug and Priority Review Designations for AGAMREE® (Vamorolone) in South Korea
June 2, 2026
Santhera’s Shareholders Approve all Board Proposals at Today’s Annual General Meeting
May 26, 2026